검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | TS-1 |
Overview Company | Takara Bio Inc. |
Overview Modality | CGT |
Overview Target | Pancreatic Cancer Stage III |
Overview Indication | Pancreatic Cancer Stage III; Pancreatic Cancer Stage IV |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | inhibits endometrial cancer cell proliferation, migration, and apoptosis by blocking the PI3K/AKT/mTOR signaling pathway |
MoA Biomarker | biomarkers for diagnosing and understanding TS mechanisms |
PK/PD Species | Dog, Mouse |
PK/PD Animal (cat.) | Mouse, Dog, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Dog, Mouse |
Toxicology Animal (cat.) | Mouse, Dog, In vitro |
Toxicology Major finding | pneumonitis and skin toxicity were observed, but nonhematological toxicities occurred at ge |
Clinical Primary efficacy | ORR 72.2% |
Clinical ORR | 72.2% |
Clinical PFS | 9.4 |
Clinical OS | 16.9 |
Clinical Result source | ClinicalTrials.gov NCT03382600 |
Clinical Data Tier / Score | A · 64 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | TS-1 |
Overview Company | Takara Bio Inc. |
Overview Modality | CGT |
Overview Target | Pancreatic Cancer Stage III |
Overview Indication | Pancreatic Cancer Stage III; Pancreatic Cancer Stage IV |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | inhibits endometrial cancer cell proliferation, migration, and apoptosis by blocking the PI3K/AKT/mTOR signaling pathway |
MoA Biomarker | biomarkers for diagnosing and understanding TS mechanisms |
PK/PD Species | Dog, Mouse |
PK/PD Animal (cat.) | Mouse, Dog, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Dog, Mouse |
Toxicology Animal (cat.) | Mouse, Dog, In vitro |
Toxicology Major finding | pneumonitis and skin toxicity were observed, but nonhematological toxicities occurred at ge |
Clinical Primary efficacy | ORR 72.2% |
Clinical ORR | 72.2% |
Clinical PFS | 9.4 |
Clinical OS | 16.9 |
Clinical Result source | ClinicalTrials.gov NCT03382600 |
Clinical Data Tier / Score | A · 64 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교